Background
- Next-generation sequencing (NGS) is standard of care in metastatic non-small cell lung cancer (NSCLC)
- Targeted therapy has transformed outcomes for driver mutation-positive tumors
- Copy number amplifications (CNA) of driver oncogenes are also frequently detected via NGS -interpretation and clinical impact is less clear
- ERBB2, KRAS and MET are oncogenic driver genes with intersecting resistance mechanisms and evolving therapeutic landscapes